|Videos|June 19, 2023

A 75-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer

Author(s)Alicia K. Morgans, MD, MPH

Expert oncologist Alicia Morgans, MD, MPH, shares details on the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Episodes in this series

Expert on prostate cancer

EP. 1 A 75-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer

Expert on prostate cancer

EP. 2 Treatment Options for Patients With Metastatic Castration-Resistant Prostate Cancer

Expert on prostate cancer

EP. 3 CARD Trial: Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Expert on prostate cancer

EP. 4 Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC: VISION and TheraP Trials

Expert on prostate cancer

EP. 5 Where Does Lutetium Lu 177 Vipivotide Tetraxetan Fit Into the mCRPC Treatment Landscape?

Expert on prostate cancer

EP. 6 mCRPC: Practical Considerations for Real World Use of Lutetium Lu 177 Vipivotide Tetraxetan

Expert on prostate cancer

EP. 7 mCRPC Treatment Landscape: Key Takeaways and Clinical Pearls

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Prostate and Rare Cancer Agents Nab FDA Fast Track Status

October 9th, 2026

Prostate and Rare Cancer Agents Nab FDA Fast Track Status

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Amivantamab vs. Emerging EGFR Bispecifics in HNSCC

Durability of PFS and OS Benefit vs. Historical Control

Weighing Logistics and Time Savings of Subcutaneous Drug Delivery

VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors

Designing Clinical Trials for Real-World Access